Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 3

Status

Recruiting 3

Sponsor Class

INDUSTRY 19OTHER 11NIH 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Sarcoma, Kaposi 1Sarcoma 1Neurofibromatosis 1 1Liposarcoma 1Leiomyosarcoma 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 44Biopsy 35Specimen Handling 33Magnetic Resonance Spectroscopy 30fludarabine 27aldesleukin 26Filgrastim 20Carboplatin 20Paclitaxel 19fludarabine phosphate 17Rituximab 17Sirolimus 16Cisplatin 16Temozolomide 15Radiotherapy 14Etoposide 14Bevacizumab 14Prednisone 13Gemcitabine 13Docetaxel 13Cytarabine 13Erlotinib Hydrochloride 12Fluorouracil 11Vorinostat 10Vincristine 10Sorafenib 10Electrocardiography 10Doxorubicin 10temsirolimus 9pembrolizumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × abemaciclib × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT04941274 2026-05-05

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
111 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT04750928 2026-04-24

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
55 enrolled
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡